Jan 1, 2000
Citations
0
Influential Citations
0
Citations
Journal
Expert Opinion on Therapeutic Patents
Abstract
Novel 2-(alkylaminoalkyl)amino-3-aryl-6,7-dichloroquinoxalines are claimed that act as selective antagonists of IL-8. Specified examples inhibit IL-8 induced chemotaxis of human neutrophils with IC50 values in the 80 to 400 nM range. Such compounds provide a novel class of anti-inflammatory agents especially suitable for the treatment of neutrophil mediated inflammatory diseases.